Bris­tol My­ers re­ports short­age of chemo drug abrax­ane; Sar­to­rius more than dou­bles ca­pac­i­ty with Michi­gan ex­pan­sion

Man­u­fac­tur­ing de­lays have led to a short­age in abrax­ane, Bris­tol My­ers Squibb says.

The an­nounce­ment comes on the heels of the FDA shoot­ing down a pe­ti­tion to stall gener­ic ver­sion of the drug. Five years af­ter the pe­ti­tion was filed, the FDA re­ject­ed it com­plete­ly in Ju­ly. The chemother­a­py drug brought in more than $1.2 bil­lion for Bris­tol My­ers in 2020.

The short­age af­fects 100 mg vials of the in­tra­venous lyophilized pow­der.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.